<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901496</url>
  </required_header>
  <id_info>
    <org_study_id>H-16018062</org_study_id>
    <nct_id>NCT02901496</nct_id>
  </id_info>
  <brief_title>Ectopic Adipose Tissue, Exercise Training and IL-6</brief_title>
  <official_title>Ectopic Adipose Tissue, Exercise Training and IL-6 - A Human Intervention Study Investigating the Role of Exercise Training on Ectopic Adipose Tissue and Gastric Emptying - Mechanisms of Action.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: Exercise training improves the risk of cardiometabolic diseases; yet the underlying
      mechanisms are unclear. Exercise induces release of IL-6 from skeletal muscle. Acute
      elevations in IL-6 improve lipid and glucose metabolism, the latter partly through a delayed
      gastric emptying. Physical inactivity causes accumulation of visceral fat (VAT). Visceral and
      epicardial adipose tissue (EAT) is more inflamed than subcutaneous adipose tissue. Thus, the
      investigators hypothesize that exercise-induced IL-6 mediates the exercise-induced reduction
      in EAT and VAT. Secondly, the investigators hypothesize that exercise-induced adaptations in
      glucose metabolism and gastric motility are dependent on IL-6. Finally the investigators
      hypothesise that both endurance and resistance exercise training reduce VAT and EAT.

      Primary aim: To investigate the effects of exercise training on VAT and to determine to what
      extend IL-6 mediates this effect.

      Secondary aims: 1) To determine whether 12 weeks of endurance and strength training can
      reduce the amount of EAT. 2) To study whether the effects of exercise on glucose metabolism
      and gastric emptying are dependent on IL-6.

      Methods: Inclusion: 70 inactive men and women, &gt;18 years, waist to height ratio &gt; 0.5 and/or
      waist circumference ≥ 88 cm (women); waist circumference ≥ 102 cm (men) Design: A 12-week,
      double-blinded randomised, placebo-controlled exercise intervention study.

      Intervention: Subjects will be randomised to one of five groups: i) Tocilizumab (IL-6
      receptor antibody) and endurance training, ii) Placebo to Tocilizumab and endurance training,
      iii) Tocilizumab, no exercise iv) Placebo to Tocilizumab and no training, and v) Placebo to
      Tocilizumab, and resistance training. Tocilizumab/placebo dose will be administered
      (according to standard recommendations) before the first training session, and maintained
      during the 12-week training program. Training will be supervised to ensure intensity and
      compliance. Subjects will be instructed not to change eating habits and informed that this
      study does not aim for a weight loss.

      Statistical considerations: Study investigators are blinded to treatment allocation. Dropouts
      will be replaced. A sample size of 70 subjects is needed to detect a 10% change in visceral
      adipose, with a power of 80% and a significance level of 0.05.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in visceral fat mass</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>Visceral fat mass will be measured by MRI before and after the intervention. Difference in change in visceral fat mass from baseline to 12 weeks follow up will be compared between group: Endurancetraining + tocilizumab and group: Endurancetraining + placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in visceral fat mass</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>Difference in change in visceral fat mass from baseline to 12 weeks follow up will be compared between group: Endurancetraining + placebo and group: no training + placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in visceral fat mass</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>2. Difference in change in visceral fat mass from baseline to 12 weeks follow up will be compared between group: Endurancetraining + placebo and group: resistance training + placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in visceral fat mass</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>3. Difference in change in visceral fat mass from baseline to 12 weeks follow up will be compared between group: Endurancetraining + tocilizumab and group: no training + tocilizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in visceral fat mass</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>4. Difference in change in visceral fat mass from baseline to 12 weeks follow up will be compared between group: resistance training + placebo and group: no training + placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in visceral fat mass</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>5. Difference in change in visceral fat mass from baseline to 12 weeks follow up will be compared between group: no training + placebo and group: no training + tocilizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epicardial adipose tissue</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>Cardiac fat volume will be measured by a cardiac MRI scan before and after the interventions. All groups will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>Gastric emptying will be measured by paracetamol blood levels (mmol/l) before and after the interventions.
The paracetamol levels will be compared between groups as follows. Group: Endurancetraining + tocilizumab and group: Endurancetraining + placebo. Group: Endurancetraining + placebo and group: no training + placebo. Group: Endurancetraining + tocilizumab and group: no training + tocilizumab. Group: No training + placebo and group: no training + tocilizumab.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peri- and paracardial adipose tissue volume (measured by MRI)</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body composition analysis (measured by Dual-energy X-ray absorptiometry)</measure>
    <time_frame>0, 4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Waist circumference (measured in cm)</measure>
    <time_frame>0, 4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BMI (kg/m^2, weight in kilograms, height in meters)</measure>
    <time_frame>0, 4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Resting blood pressure as a measure of cardiovascular function</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximal aerobic capacity (cardiovascular fitness) (VO2 peak)</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Muscle strength measured by one repetition maximum (1RM)</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glycemic control during mixed meal tolerance test</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Free-living glycemic control using continuous glucose monitoring</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pro- and anti-inflammatory cytokines(Interleukin-6, Interleukin-1ra, Interleukin-1, Interleukin-18, Interleukin-15, Interleukin-10)</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>soluble Interleukin-6 receptor (sIL-6R)</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>soluble gp130</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adipose characteristic by blood markers</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
    <description>Blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Cortisol</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
    <description>Blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Catecholamines (Epinephrine and norepinephrine)</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>leukocytes</measure>
    <time_frame>0,4, 8 and 12 weeks, (Timepoints: 0, 22, 45, 01:45, 02:45, at week 0 and 12)</time_frame>
    <description>Blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
    <description>blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood lipid</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
    <description>Blood sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular function assessed by blood markers</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation status assessed by blood markers</measure>
    <time_frame>0,4, 8 and 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adipose biopsy to assess the adipokine expression signature</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Photo of subjects</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>To asses if the visual appearance of the stomach is reflecting the amount of visceral fat mass and to see if there is a difference in the visual appearance before and after the intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Faecal and urine samples to asses changes in the microbiome</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in sleepiness</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>Self-report using the Epworth questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Exercise factors during an acute exercise bout</measure>
    <time_frame>Timepoints: 0, 22, 45, 01:45, 02:45, before and after the intervention (0,12 weeks)</time_frame>
    <description>cortisol, il-6, epinephrine and norepinephrine</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose metabolism during an acute exercise bout</measure>
    <time_frame>Timepoints: 0, 22, 45, 01:45, 02:45, before and after the intervention (0,12 weeks)</time_frame>
    <description>At each timepoint exercise factors: cortisol, il-6, epinephrine and norepinephrine will be measured. Furthermore pro anti-inflammatory cytokines, glucose, insulin, C-peptide, C-reactive protein will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Whole blood stimulation with Lipopolysaccharide and phytohaemagglutinin</measure>
    <time_frame>During the acute exercise bout at Timepoints: 0, 22, 45, 01:45, 02:45, before and after the intervention (0,12 weeks)</time_frame>
    <description>in vitro stimulation of whole blood.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fibroblast growth factor 21</measure>
    <time_frame>During the acute exercise bout at Timepoints: 0, 22, 45, 01:45, 02:45, before and after the intervention (0,12 weeks)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>oxidative burst in neutrophils</measure>
    <time_frame>During the acute exercise bout at Timepoints: 0, 22, 45, 01:45, 02:45, before and after the intervention (0,12 weeks)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>gastrointestinal health</measure>
    <time_frame>0,12 weeks</time_frame>
    <description>A questionnaire regarding gastrointestinal symptoms. A Visual Analog Score will be used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>0 weeks</time_frame>
    <description>Self-report physical activity using The Minnesota Leisure Time Physical Activity Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Diet registration</measure>
    <time_frame>0,4,12</time_frame>
    <description>Self-report diet registration for 3 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Satiety</measure>
    <time_frame>0,12</time_frame>
    <description>self-report using a satiety questionnaire during mixed meal tolerance test</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac function measured by heart rate recovery</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Muscle biopsy to assess expression of exercise induced cytokines</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Coronary sinus flow reserve as a measure of global perfusion using MRI</measure>
    <time_frame>0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Insulin during mixed meal tolerance test</measure>
    <time_frame>Time Frame: 0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>C-peptide during mixed meal tolerance test</measure>
    <time_frame>Time Frame: 0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon during mixed meal tolerance test</measure>
    <time_frame>Time Frame: 0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>GLP-1 during mixed meal tolerance test</measure>
    <time_frame>Time Frame: 0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Insulin sensitivity index (Matsuda) based on mixed meal tolerance test</measure>
    <time_frame>Time Frame: 0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Insulin secretion index based on mixed meal tolerance test</measure>
    <time_frame>Time Frame: 0, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>IL-6 released in respons to an exercise bout</measure>
    <time_frame>one of the first 3 and one of the last 3 exercise bouts</time_frame>
    <description>IL-6 in plasma measured before and after an exercise bout</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Adiposity</condition>
  <arm_group>
    <arm_group_label>Endurance exercise + infusion of Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endurance exercise training + monthly infusion of Tocilizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endurance exercise + infusion of placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endurance exercise training + monthly infusion of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No exercise + infusion of Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No exercise + monthly infusion of Tocilizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No exercise + infusion of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No exercise training + monthly infusion of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resistance exercise + infusion of placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resistance exercise training + monthly infusion of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Endurance Exercise Training</intervention_name>
    <description>Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max</description>
    <arm_group_label>Endurance exercise + infusion of Tocilizumab</arm_group_label>
    <arm_group_label>Endurance exercise + infusion of placebo</arm_group_label>
    <other_name>Endurance exercise</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Resistance Exercise Training</intervention_name>
    <description>Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.</description>
    <arm_group_label>Resistance exercise + infusion of placebo</arm_group_label>
    <other_name>Resistance exercise</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No Exercise</intervention_name>
    <description>Control to exercise</description>
    <arm_group_label>No exercise + infusion of Tocilizumab</arm_group_label>
    <arm_group_label>No exercise + infusion of placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.</description>
    <arm_group_label>Endurance exercise + infusion of Tocilizumab</arm_group_label>
    <arm_group_label>No exercise + infusion of Tocilizumab</arm_group_label>
    <other_name>RoActemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.</description>
    <arm_group_label>Endurance exercise + infusion of placebo</arm_group_label>
    <arm_group_label>No exercise + infusion of placebo</arm_group_label>
    <arm_group_label>Resistance exercise + infusion of placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  Sedentary

          -  Waist to height ratio ≥ ½ and/or waist circumference ≥ 88 cm (women); waist
             circumference ≥ 102 cm (men)

          -  Age ≥ 18 y

        Exclusion Criteria:

          -  Pregnancy

          -  Diagnosed with diabetes (HbA1c ≥ 48 mmol/mol or fasting glucose ≥ 7.0 mmol/l)

          -  Diagnosed with ischemic heart disease

          -  Atrial fibrillation

          -  Treatment with biologic rheumatic drugs, systemic prednisolone or other
             immunosuppressive treatments

          -  Health conditions that prevents individuals from participating in the exercise
             training intervention e.g. severe obesity

          -  Patients who cannot undergo MRI scans (e.g. kidney disease, metallic implants or
             claustrophobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente K Pedersen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louise L Lehrskov, MD</last_name>
    <phone>+45 35457190</phone>
    <email>louise.lang.lehrskov@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Sophie wedel-Neergaard, MD</last_name>
    <phone>+45 35457190</phone>
    <email>anne-sophie.wedell-neergaard.02@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet, Centre of Inflammation and Metabolism (CIM) Centre for Physical Activity Research (CFAS)</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise L Lehrskov, MD</last_name>
      <phone>+45 35457190</phone>
      <email>louise.lang.lehrskov@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Louise L Lehrskov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regitse H Christensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie Wedel-Neergard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Louise Lang Lehrskov</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

